Asset profile
FB-101
Small molecule
Evidence outlook · lead readout
NCT04165837 · Parkinson's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04165837: Participants were randomized to FB-101 or placebo with blinding of participants, care providers, and investigators, but the primary endpoint is adverse-event incidence in healthy volunteers rather than a Parkinson's disease outcome, and no results have been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.